Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Phibro Animal Health (PAHC) Other financing activities (2022 - 2024)

Phibro Animal Health has reported Other financing activities over the past 3 years, most recently at $10.4 million for Q3 2024.

For Q3 2024, Other financing activities changed N/A year-over-year to $10.4 million; the TTM value through Jun 2025 reached $10.4 million, changed N/A, while the annual FY2025 figure was $10.4 million, N/A changed from the prior year.
Other financing activities for Q3 2024 was $10.4 million at Phibro Animal Health, up from $833000.0 in the prior quarter.
Over five years, Other financing activities peaked at $10.4 million in Q3 2024 and troughed at $71000.0 in Q3 2022.
A 3-year average of $3.0 million and a median of $701000.0 in 2022 define the central range for Other financing activities.